Fitness & Wellness Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness & Wellness Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diarrhea
Study findings on diarrhea are outlined in reports from E. Kokkotou and colleagues
May 21st, 2008
"Clostridium difficile-associated colitis is an increasing cause of morbidity and mortality in hospitalized patients, with high relapse rates following conventional therapy. We sought to determine the efficacy of rifaximin, a novel nonabsorbed antibiotic, in the hamster model of C difficile-associated diarrhea (CDAD)," scientists in the United States report. "Hamsters received clindamycin subcutaneously and 24 h later were infected by gavage with one of two C. difficile strains: a reference strain (VPI 10463) and a current epidemic strain (BI17). Vancomycin (50 mg/kg of body weight) or rifaximin (100, 50, and 25 mg/kg) were then administered orally for 5 days beginning...
Source: Fitness & Wellness Business Week (2008-05-21)
|
